Relay Therapeutics, Inc.
RLAY
$3.26
$0.061.88%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 100.00% | -- | -- | 4,327.88% | -100.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 100.00% | -- | -- | 4,327.88% | -100.40% |
| Cost of Revenue | -12.78% | -5.98% | 4.30% | -0.51% | 15.55% |
| Gross Profit | 12.78% | -36.11% | -4.44% | 12.35% | -16.01% |
| SG&A Expenses | 0.76% | 6.84% | 0.09% | 1.12% | 3.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.85% | -3.61% | 3.52% | -0.20% | 12.69% |
| Operating Income | 9.85% | -28.88% | -3.63% | 9.77% | -13.03% |
| Income Before Tax | 8.97% | -34.03% | 6.39% | 13.64% | -23.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.97% | -34.03% | 6.39% | 13.64% | -23.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.97% | -34.03% | 6.39% | 13.64% | -23.69% |
| EBIT | 9.85% | -28.88% | -3.63% | 9.77% | -13.03% |
| EBITDA | 9.95% | -29.41% | -3.64% | 10.08% | -12.96% |
| EPS Basic | 32.14% | -16.83% | 14.23% | 19.93% | -19.95% |
| Normalized Basic EPS | 33.78% | -14.72% | 5.73% | 18.99% | -6.32% |
| EPS Diluted | 32.14% | -16.83% | 14.23% | 19.93% | -19.95% |
| Normalized Diluted EPS | 33.78% | -14.72% | 5.73% | 18.99% | -6.32% |
| Average Basic Shares Outstanding | 34.14% | 14.72% | 9.16% | 7.85% | 3.13% |
| Average Diluted Shares Outstanding | 34.14% | 14.72% | 9.16% | 7.85% | 3.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |